Results 191 to 200 of about 1,914,857 (292)

University strategy in transnational higher education: The strategic approaches of newly established and ‘small’ international branch campuses

open access: yesBritish Educational Research Journal, EarlyView.
Abstract Newly established international branch campuses (IBCs) commence operations without a student body, and even after several years, many institutions fail to grow beyond 500 students. Despite having unique strategic needs, small IBCs are largely overlooked in the higher education literature.
Stephen Wilkins, Joe Hazzam
wiley   +1 more source

How curriculum modifications shape educational pathways: Evidence from linked administrative data in Switzerland

open access: yesBritish Educational Research Journal, EarlyView.
Abstract The increasing heterogeneity of learning needs and preconditions in inclusive mainstream classrooms entails that not all learners are equally able to meet the regular learning objectives. In response, various integrative measures have been implemented to tailor instruction to students' individual needs.
Robin Benz   +2 more
wiley   +1 more source

Reframing Colonial Korea's Forests Through Protection Forests: The Forests of Joseon (1938)

open access: yesBerichte zur Wissenschaftsgeschichte, EarlyView.
This study examines The Forests of Joseon (1938), a forestry survey compiled by Tokumitsu Nobuyuki under Japanese colonial rule, as a key site of epistemic negotiation between imperial forestry science and Korean indigenous knowledge. Focusing on bíbo forests—geomantic forests believed to regulate energy flow between mountains and villages—the paper ...
Soyeong Park, Jeong‐Hann Pae
wiley   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

open access: yesBiotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga   +2 more
wiley   +1 more source

Federal Lobbyist Spending to Influence 340B Drug Pricing Program Policy.

open access: yesJAMA Netw Open
Urban C, Shore C, Desai S, Taylor L.
europepmc   +1 more source

Home - About - Disclaimer - Privacy